Autopsy report · NCT01447394
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
Cause of deathNo reason given
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Pegylated Interferon Lambda; Pegylated Interferon Alfa-2a; Ribavirin
- Participants
- 0
- Sites
- 100
- Countries
- Canada, China, Colombia, Czechia, Egypt, Hong Kong, Hungary, India, Ireland, Netherlands, Poland, Romania and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.